Development of a Clinical Prediction Model for Systemic Therapy Escalation in Oral Lichen Planus: A Two-Center Retrospective Cohort Study.
4 affiliations
- 1Department of Surgicals, Faculty of Dental Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- 2Dermatology Clinic, Railways University Hospital, 700506 Iasi, Romania.
- 3Ambulatory of Oral and Maxillofacial Surgery of the "St. Spiridon" County Clinical Emergency Hospital, 700106 Iași, Romania.
- 4Department of Dermatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Abstract
Background and Objectives: Oral lichen planus (OLP) is a chronic immune-mediated disorder in which the need for systemic therapy remains difficult to predict using standardized clinical criteria. This retrospective two-center cohort study aimed to develop a multivariable clinical prediction model for systemic therapy escalation in patients with histopathologically confirmed OLP. Material and Methods: Medical records of 141 adult patients treated between 2022 and 2025 were reviewed. Baseline demographic, clinical, and laboratory variables were analyzed using univariate analyses, followed by multivariable logistic regression with backward stepwise selection and Firth penalized likelihood estimation. Discrimination was assessed by the area under the ROC curve (AUC), and internal validation was performed by bootstrap resampling (1000 samples) with repetition of the full selection procedure. Results: Four independent predictors of systemic therapy were identified: concomitant cutaneous lichen planus (penalized odds ratio (OR) 13.96, 95% CI 3.94-55.84), autoimmune thyroiditis (OR 12.67, 3.26-54.88), genital lichen planus (OR 10.21, 2.36-51.57) and oral Candida superinfection (OR 4.48, 1.10-18.82). The apparent AUC was 0.889 (95% CI 0.801-0.976); after bootstrap internal validation, the optimism-corrected AUC was 0.84 and the calibration slope 0.73, indicating moderate overfitting. Candida superinfection was the least stable predictor (selected in 43% of bootstrap samples). A prognostic risk matrix was developed to estimate the probability of systemic therapy escalation according to different combinations of predictors. Conclusions: The identified clinical factors and derived risk matrix may provide a preliminary framework for risk stratification and individualized therapeutic decision-making in patients with OLP. However, given the retrospective design and limited number of outcome events, these findings should be interpreted cautiously. Prospective external validation in larger independent cohorts is required before the model can be considered for routine clinical use.
Related
- Development and internal validation of an exploratory clinical prediction model for MRI-defined white matter injury in moderate-to-late preterm infants: a single-center retrospective study
- Development and validation of a clinical prediction model for diagnosing nephrotic syndrome in adults: a retrospective diagnostic prediction study
- Development of a nomogram for preoperative prediction of malignant risk in thyroid follicular tumors based on multimodal ultrasound and clinical features: A retrospective observational study
- Development and Internal Validation of a Clinical Prediction Model for Coronary Slow Flow Phenomenon in Type 2 Diabetes: A Retrospective Observational Study.
- Development and validation of a simple clinical prediction model for post-stroke seizures in critically ill patients: a multicenter retrospective cohort study
BibTeX
@article{toader2026development,
title = {{Development of a Clinical Prediction Model for Systemic Therapy Escalation in Oral Lichen Planus: A Two-Center Retrospective Cohort Study.}},
author = {Mihaela Paula Toader and Cristina Popa and Cristina Colac-Boțoc and Ana Maria Sciucă and Anastasia Vicovan and Daciana Elena Brănișteanu},
journal = {Medicina (Kaunas, Lithuania)},
year = {2026},
month = oct,
doi = {10.3390/medicina62102041},
url = {https://europepmc.org/article/MED/42942572},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development of a Clinical Prediction Model for Systemic Therapy Escalation in Oral Lichen Planus: A Two-Center Retrospective Cohort Study.
AU - Mihaela Paula Toader
AU - Cristina Popa
AU - Cristina Colac-Boțoc
AU - Ana Maria Sciucă
AU - Anastasia Vicovan
AU - Daciana Elena Brănișteanu
PY - 2026
DA - 2026/10/21
JO - Medicina (Kaunas, Lithuania)
DO - 10.3390/medicina62102041
UR - https://europepmc.org/article/MED/42942572
AB - Background and Objectives: Oral lichen planus (OLP) is a chronic immune-mediated disorder in which the need for systemic therapy remains difficult to predict using standardized clinical criteria. This retrospective two-center cohort study aimed to develop a multivariable clinical prediction model for systemic therapy escalation in patients with histopathologically confirmed OLP. Material and Methods: Medical records of 141 adult patients treated between 2022 and 2025 were reviewed. Baseline demographic, clinical, and laboratory variables were analyzed using univariate analyses, followed by multivariable logistic regression with backward stepwise selection and Firth penalized likelihood estimation. Discrimination was assessed by the area under the ROC curve (AUC), and internal validation was performed by bootstrap resampling (1000 samples) with repetition of the full selection procedure. Results: Four independent predictors of systemic therapy were identified: concomitant cutaneous lichen planus (penalized odds ratio (OR) 13.96, 95% CI 3.94-55.84), autoimmune thyroiditis (OR 12.67, 3.26-54.88), genital lichen planus (OR 10.21, 2.36-51.57) and oral Candida superinfection (OR 4.48, 1.10-18.82). The apparent AUC was 0.889 (95% CI 0.801-0.976); after bootstrap internal validation, the optimism-corrected AUC was 0.84 and the calibration slope 0.73, indicating moderate overfitting. Candida superinfection was the least stable predictor (selected in 43% of bootstrap samples). A prognostic risk matrix was developed to estimate the probability of systemic therapy escalation according to different combinations of predictors. Conclusions: The identified clinical factors and derived risk matrix may provide a preliminary framework for risk stratification and individualized therapeutic decision-making in patients with OLP. However, given the retrospective design and limited number of outcome events, these findings should be interpreted cautiously. Prospective external validation in larger independent cohorts is required before the model can be considered for routine clinical use.
SN - 1010-660X
SN - 1648-9144
ER -